Skip to main content Accessibility help

Assessment of the clinical relevance of quantitative sensory testing with Von Frey monofilaments in patients with allodynia and neuropathic pain. A pilot study

  • D. Keizer (a1), M. van Wijhe (a1), W. J. Post (a2), D. R. A. Uges (a3) and J. M. K. H. Wierda (a1)...



Allodynia is a common and disabling symptom in many patients with neuropathic pain. Whereas quantification of pain mostly depends on subjective pain reports, allodynia can also be measured objectively with quantitative sensory testing. In this pilot study, we investigated the clinical relevance of quantitative sensory testing with Von Frey monofilaments in patients with allodynia as a consequence of a neuropathic pain syndrome, by means of correlating subjective pain scores with pain thresholds obtained with quantitative sensory testing.


During a 4-week trial, we administered a cannabis extract to 17 patients with allodynia. We quantified the severity of the allodynia with Von Frey monofilaments before, during and after the patients finished the trial. We also asked the patients to rate their pain on a numeric rating scale at these three moments.


We found that most of the effect of the cannabis occurred in the last 2 weeks of the trial. In this phase, we observed that the pain thresholds, as measured with Von Frey monofilaments, were inversely correlated with a decrease of the perceived pain intensity.


These preliminary findings indicate clinical relevance of quantitative sensory testing with Von Frey monofilaments in the quantification of allodynia in patients with neuropathic pain, although confirmation of our data is still required in further studies to position this method of quantitative sensory testing as a valuable tool, for example, in the evaluation of therapeutic interventions for neuropathic pain.


Corresponding author

Correspondence to: Doeke Keizer, Department of Anesthesiology, Pain Management Center, University Medical Center Groningen, P. O. Box 30001,9700 RB Groningen, The Netherlands. E-mail:; Tel:+31 050 3614886; Fax: +31 050 3619317


Hide All
1.Macres, SM, Richeimer, SH, Duran, PJ. The pathophysiology and treatment of neuropathic pain. Am Soc Anesthesiol 1999; 27: 109121.
2.Woolf, CJ, Mannion, RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 19591964.
3.Bridges, D, Thompson, SWN, Rice, ASC. Mechanisms of neuropathic pain. Br J Anaesth 2001; 87: 1226.
4.Merskey, H, Bogduk, N. eds. Classification of chronic pain. Seattle: IASP Press, 1994.
5.Hansson, PT, Lacerenza, M, Marchettini, P. Aspects of clinical and experimental neuropathic pain: the clinical perspective In: Hansson, PT, Fields, HL, Hill, RG, Marchettini, P. eds. Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management, Vol. 21. Seattle: IASP Press, 2001: 118.
6.Backonja, MM. Painful neuropathies In: Loeser, JD. ed. Bonica’s Management of Pain. Philadelphia: Lippincott Williams & Wilkins, 2002: 371387.
7.Chapman, CR, Syrjala, KL. Measurement of pain In: Bonica, JJ. ed. The management of pain. Philadelphia: Lea & Febiger, 1990: 580594.
8.Atcheson, R. Physiology and measurement of pain In: Aitkenhead, AR, Rowbotham, DJ, Smith, G. eds. Textbook of anaesthesia. London: Churchill Livingstone, 2001: 201210.
9.Edwards, RR, Sarlani, E, Wesselmann, U, Fillingim, RB. Quantitative assessment of experimental pain perception: multiple domains of clinical relevance. Pain 2005; 114: 315319.
10.Peripheral Neuropathy Association. Quantitative sensory testing: a consensus report from the peripheral neuropathy association. Neurology 1993; 43: 10501052.
11.Keizer, D, Wijhe van, M, Post, WJ, Wierda, JMKH. Quantifying allodynia in patients suffering from unilateral neuropathic pain using Von Frey monofilaments. Clin J Pain 2007; 23: 8590.
12.Bell-Krotoski, J, Tomancik, E. The repeatability of testing with Semmes–Weinstein monofilaments. J Hand Surg 1987; 12A: 155161.
13.Mikkelsen, T, Werner, MU, Lassen, B, Kehlet, H. Pain and sensory dysfunction 6 to 12 months after inguinal herniotomy. Anaesth Analg 2004; 99: 146151.
14.Campbell, FA, Tramèr, MR, Carroll, D, Reynolds, DJM, Moore, RA, McQuay, HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 16.
15.Kumar, RN, Chambers, WA, Pertwee, RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001; 56: 10591068.
16.Iversen, L, Chapman, V. Cannabinoids: a real prospect for pain relief? Cur Opin Pharmacol 2002; 2: 5055.
17.Rukwied, R, Watkinson, A, McGlone, F, Dvorak, M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 102: 283288.
18.Voerman, VF, Egmond van, J, Crul, BJP. Elevated detection thresholds for mechanical stimuli in chronic pain patients: support for a central mechanism. Arch Phys Med Rehabil 2000; 81: 430435.
19.Price, DD, Bennett, GJ, Raffii, A. Psychophysical observations on patients with neuropathic pain relieved by a sympathetic block. Pain 1989; 36: 273288.
20.Gruener, G, Dyck, PJ. Quantitative sensory testing: methodology, application, and future directions. J Clin Neurophysiol 1994; 11: 568583.
21.Dotson, RM. Clinical neurophysiology laboratory tests to assess the nociceptive system in humans. J Clin Neurophysiol 1997; 14: 3245.
22.Sorensen, J, Bengtsson, A, Ahlner, J, Henriksson, KG, Ekselius, L, Bengtsson, M. Fibromyalgia – are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997; 24: 16151621.
23.Martin, WJ, Loo, CM, Basbaum, AI. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999; 82: 199205.
24.Farquhar-Smith, WP. Pain and cannabinoids: science and evidence. Pain Reviews 2002; 9: 4167.
25.Mather, LE. Medicinal cannabis – Hoax or hope? Reg Anesth Pain Med 2001; 26: 484487.


Assessment of the clinical relevance of quantitative sensory testing with Von Frey monofilaments in patients with allodynia and neuropathic pain. A pilot study

  • D. Keizer (a1), M. van Wijhe (a1), W. J. Post (a2), D. R. A. Uges (a3) and J. M. K. H. Wierda (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed